LABORATORY MANAGEMENT
we had international colleagues come over to visit us in autumn 2023 to run workshops. They enabled us to evaluate our progress: we have the chance to test the next bits of software, we can determine where the gaps are, and we can start to plan where we want to go in the future, as we consider what might be cost-effective with the current set up, and where we might have opportunities to expand. We’ve already seen major
The cobas p 612 system for pre-analytics is able to uncap samples and put them in batches before fully tracking everything, even identifying tube types and detecting liquid levels.
The advantages of having a shared
workforce and economies of scale are clear: we can load more tests on the automated system, overseen by medical laboratory assistants, staff trained to run pre-analytics, who can work on labelling and entering data – while associate practitioner staff lead on the cobas 8800 side. This includes daily, weekly, and monthly maintenance, making up kits that run on omni-channels, and handling reagents.
Our biomedical scientists, therefore, can step in to look at the results when their expertise is needed and provide validation using the cobas infinity lab middleware solution. This allows for considerable efficiency and flexibility in how we work; our biomedical scientists can manage their time optimally. As we face staffing challenges within
the broader pathology sector, the introduction of highly automated support staff led solutions like this, allows us to redirect biomedical science staff to more
grade-appropriate tasks. Getting used to multidisciplinary team working required us to adapt our usual approach, but once we got used to it the benefits were clear. However, the most important part of the integrated laboratory is that all this automation and integration is going to make a difference in the TAT of these tests, which means patients can be treated earlier. Now that all of our 24/7 services are in one space, they will never work alone again. The equipment will allow LCL to take part in the response to any future public health issues, such as pandemics, in a timely way.
Looking to the future It’s no small feat to launch an integrated laboratory, and we are constantly working on our offering and improving. But we knew we weren’t heading into it blind: Roche has been our long-term managed service partner, so we knew that we would work well together.
This is a new step in that partnership,
improvements in our sexual health service TAT, a major user of molecular services at LCL, which means that we can quickly respond to the needs of our patients and meet the demands of the service. As NHS diagnostic providers aim to embrace 24/7 working, the built-in efficiency of this automated molecular service will help us reap the benefits. We are now actively collaborating with Roche Diagnostics on future developments, such as the future assay catalogue and what it might look like. We’ve achieved so much and look forward to continuing to go from strength to strength.
Karl McIntyre joined Liverpool Clinical Laboratories in January 2019 as Head of IT and Transformation. Having previously spent 12 years at St Helens and Knowsley Hospitals Health Informatics Service, Karl has a breadth of experience within health service IT. Karl has implemented large clinical system implementations such as PAS, PACS, e-Prescribing, EDMS and Results Reporting. He is an experienced business change lead, having worked closely with clinical and administration staff on process re-design and adoption.
This article was written in collaboration and with support of Roche Diagnostics.
www.liverpoolcl.nhs.uk www.diagnostics.roche.com
Severn Biotech
www.severnbiotech.com
reagents
Tel: +44 (0)1562 825286 Fax: +44 (0)1562 825284 E-mail:
info@servernbiotech.com
Our reagents are made from the highest quality pure materials to exact standards. ISO 9001 : 2015 accredited.
WWW.PATHOLOGYINPRACTICE.COM SEPTEMBER 2024 29
molecular biology/lab
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
